TTrialPathMatch Me to Trials
← Back to trials
RecruitingHealthy VolunteerAtopic Dermatitis

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Eligible age

18–65 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Sponsor: Regeneron Pharmaceuticals

Where it's recruiting

Alabama

Birmingham

California

West Hills

South Carolina

North Charleston

Texas

San Antonio

Source: ClinicalTrials.gov · NCT07527923 · last updated 2026-09-25

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants · TrialPath